SAN DIEGO, Nov. 08, 2018 (GLOBE NEWSWIRE) — aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced that it will report its third quarter financial results on Tuesday, November 13, 2018 after the close of the U.S. financial markets. Company management will host a conference call and audio webcast on Tuesday, November 13, 2018 at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss the results and provide a corporate update.

Interested parties may access the call by dialing toll-free (844) 358-9116 from the U.S. or (209) 905-5951 internationally and using conference ID 4389274.

The press release and links to a live audio webcast and replay may be accessed on the aTyr website events page at: http://investors.atyrpharma.com/events-and-webcasts. An audio replay will be available for at least 90 days following the event. 

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways.  aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes.  aTyr is focused on the therapeutic translation of the Resokine pathway, comprised of extracellular proteins derived from the histidyl tRNA synthetase gene family. ATYR1923 is a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in interstitial lung diseases and other immune-mediated diseases.  For more information, please visit http://www.atyrpharma.com.